The revised FIGO staging system for uterine malignancies: Implications for MR imaging

Radiographics

Volumn 32, Issue 6, 2012, Pages 1805-1827

  Freeman, Susan J ^a   Aly, Ahmed M ^b   Kataoka, Masako Y ^d   Addley, Helen C ^a   Reinhold, Caroline ^c   Sala, Evis ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b CAIRO UNIVERSITY   (Egypt)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER STAGING; FEMALE; HUMAN; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; SENSITIVITY AND SPECIFICITY; UTERUS CANCER;

FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; SENSITIVITY AND SPECIFICITY; UTERINE NEOPLASMS;

EID: 84867587118     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.326125519     Document Type: Article

References (92)

1. Sala E, Wakely S, Senior E, Lomas D. MRI of malignant neoplasms of the uterine corpus and cervix. AJR Am J Roentgenol 2007;188(6):1577-1587.
2. Odicino F, Pecorelli S, Zigliani L, Creasman WT. History of the FIGO cancer staging system. Int J Gynaecol Obstet 2008;101(2):205-210.
3. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 2009; 105(2):109.
4. Frei KA, Kinkel K. Staging endometrial cancer: role of magnetic resonance imaging. J Magn Reson Imaging 2001;13(6):850-855.
5. Sironi S, Colombo E, Villa G, et al. Myometrial invasion by endometrial carcinoma: assessment with plain and gadolinium-enhanced MR imaging. Radiology 1992;185(1):207-212.
6. Cohen P, Tan AL, Penman A. The multidisciplinary tumor conference in gynecologic oncology: does it alter management? Int J Gynecol Cancer 2009;19 (9):1470-1472.
7. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100 (23):1707-1716.
8. Dowdy SC, Mariani A. Lymphadenectomy in endometrial cancer: when, not if. Lancet 2010;375 (9721):1138-1140.
9. ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009; 373(9658):125-136.
10. Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 2010;375 (9721):1165-1172.
11. Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011;378(9801):1461-1484.
12. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics: 2010. CA Cancer J Clin 2010;60(5):277-300.
13. Lagasse LD, Creasman WT, Shingleton HM, Ford JH, Blessing JA. Results and complications of operative staging in cervical cancer: experience of the Gynecologic Oncology Group. Gynecol Oncol 1980;9 (1):90-98.
14. Van Nagell JR Jr, Roddick JW Jr, Lowin DM. The staging of cervical cancer: inevitable discrepancies between clinical staging and pathologic findings. Am J Obstet Gynecol 1971;110(7):973-978.
15. Johnson W, Taylor MB, Carrington BM, Bonington SC, Swindell R. The value of hyoscine butylbromide in pelvic MRI. Clin Radiol 2007;62(11):1087-1093.
16. Brown MA. MR imaging of benign uterine disease. Magn Reson Imaging Clin N Am 2006;14(4): 439-453.
17. Sala E. Magnetic resonance imaging of the female pelvis. Semin Roentgenol 2008;43(4):290-302.
18. Wolfman DJ, Ascher SM. Magnetic resonance imaging of benign uterine pathology. Top Magn Reson Imaging 2006;17(6):399-407.
19. Yu KK, Hricak H, Subak LL, Zaloudek CJ, Powell CB. Preoperative staging of cervical carcinoma: phased array coil fast spin-echo versus body coil spin-echo T2-weighted MR imaging. AJR Am J Roentgenol 1998;171(3):707-711.
20. Balleyguier C, Sala E, Da Cunha T, et al. Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology. Eur Radiol 2011;21(5):1102-1110.
21. Kinkel K, Forstner R, Danza FM, et al. Staging of endometrial cancer with MRI: guidelines of the European Society of Urogenital Imaging. Eur Radiol 2009;19(7):1565-1574.
22. Shibutani O, Joja I, Shiraiwa M, et al. Endometrial carcinoma: efficacy of thin-section oblique axial MR images for evaluating cervical invasion. Abdom Imaging 1999;24(5):520-526.
23. Shiraiwa M, Joja I, Asakawa T, et al. Cervical carcinoma: efficacy of thin-section oblique axial T2-weighted images for evaluating parametrial invasion. Abdom Imaging 1999;24(5):514-519.
24. Chung HH, Kang SB, Cho JY, et al. Accuracy of MR imaging for the prediction of myometrial invasion of endometrial carcinoma. Gynecol Oncol 2007;104(3):654-659.
25. Ito K, Matsumoto T, Nakada T, Nakanishi T, Fujita N, Yamashita H. Assessing myometrial invasion by endometrial carcinoma with dynamic MRI. J Comput Assist Tomogr 1994;18(1):77-86.
26. Manfredi R, Mirk P, Maresca G, et al. Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning. Radiology 2004;231 (2):372-378.
27. Nakao Y, Yokoyama M, Hara K, et al. MR imaging in endometrial carcinoma as a diagnostic tool for the absence of myometrial invasion. Gynecol Oncol 2006;102(2):343-347.
28. Rockall AG, Meroni R, Sohaib SA, et al. Evaluation of endometrial carcinoma on magnetic resonance imaging. Int J Gynecol Cancer 2007;17(1):188-196.
29. Sala E, Crawford R, Senior E, et al. Added value of dynamic contrast-enhanced magnetic resonance imaging in predicting advanced stage disease in patients with endometrial carcinoma. Int J Gynecol Cancer 2009;19(1):141-146.
30. Seki H, Kimura M, Sakai K. Myometrial invasion of endometrial carcinoma: assessment with dynamic MR and contrast-enhanced T1-weighted images. Clin Radiol 1997;52(1):18-23.
31. Yamashita Y, Harada M, Sawada T, Takahashi M, Miyazaki K, Okamura H. Normal uterus and FIGO stage I endometrial carcinoma: dynamic gadolinium-enhanced MR imaging. Radiology 1993;186 (2):495-501.
32. Seki H, Azumi R, Kimura M, Sakai K. Stromal invasion by carcinoma of the cervix: assessment with dynamic MR imaging. AJR Am J Roentgenol 1997; 168(6):1579-1585.
33. Akita A, Shinmoto H, Hayashi S, et al. Comparison of T2-weighted and contrast-enhanced T1-weighted MR imaging at 1.5 T for assessing the local extent of cervical carcinoma. Eur Radiol 2011;21(9): 1850-1857.
34. Vargas HA, Akin O, Zheng J, et al. The value of MR imaging when the site of uterine cancer origin is uncertain. Radiology 2011;258(3):785-792.
35. Fujii S, Matsusue E, Kigawa J, et al. Diagnostic accuracy of the apparent diffusion coefficient in differentiating benign from malignant uterine endometrial cavity lesions: initial results. Eur Radiol 2008; 18(2):384-389.
36. McVeigh PZ, Syed AM, Milosevic M, Fyles A, Haider MA. Diffusion-weighted MRI in cervical cancer. Eur Radiol 2008;18(5):1058-1064.
37. Naganawa S, Sato C, Kumada H, Ishigaki T, Miura S, Takizawa O. Apparent diffusion coefficient in cervical cancer of the uterus: comparison with the normal uterine cervix. Eur Radiol 2005;15(1):71-78.
38. Shen SH, Chiou YY, Wang JH, et al. Diffusion-weighted single-shot echo-planar imaging with parallel technique in assessment of endometrial cancer. AJR Am J Roentgenol 2008;190(2):481-488.
39. Tamai K, Koyama T, Saga T, et al. Diffusion-weighted MR imaging of uterine endometrial cancer. J Magn Reson Imaging 2007;26(3):682-687.
40. Namimoto T, Awai K, Nakaura T, Yanaga Y, Hirai T, Yamashita Y. Role of diffusion-weighted imaging in the diagnosis of gynecological diseases. Eur Radiol 2009;19(3):745-760.
41. Funt SA, Hricak H. Ovarian malignancies. Top Magn Reson Imaging 2003;14(4):329-337.
42. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007;188(6):1622-1635.
43. Beddy P, Moyle P, Kataoka M, et al. Evaluation of depth of myometrial invasion and overall staging in endometrial cancer: comparison of diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 2012;262(2):530-537.
44. Rechichi G, Galimberti S, Signorelli M, Perego P, Valsecchi MG, Sironi S. Myometrial invasion in endometrial cancer: diagnostic performance of diffusion-weighted MR imaging at 1.5-T. Eur Radiol 2010;20(3):754-762.
45. Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22(Suppl 6):vi35-vi39.
46. Breijer MC, Timmermans A, van Doorn HC, Mol BW, Opmeer BC. Diagnostic strategies for postmenopausal bleeding. Obstet Gynecol Int 2010; 2010:850812.
47. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): uterine neoplasms. Version 3. National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Published March 20, 2012. Accessed April 1, 2012.
48. Querleu D, Planchamp F, Narducci F, et al. Clinical practice guidelines for the management of patients with endometrial cancer in France: recommendations of the Institut National du Cancer and the Société Française d'Oncologie Gynécologique. Int J Gynecol Cancer 2011;21(5):945-950.
49. Larson DM, Connor GP, Broste SK, Krawisz BR, Johnson KK. Prognostic significance of gross myometrial invasion with endometrial cancer. Obstet Gynecol 1996;88(3):394-398.
50. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355(9213): 1404-1411.
51. Hricak H, Hamm B, Semelka RC, et al. Carcinoma of the uterus: use of gadopentetate dimeglumine in MR imaging. Radiology 1991;181(1):95-106.
52. Lin G, Ng KK, Chang CJ, et al. Myometrial invasion in endometrial cancer: diagnostic accuracy of diffusion-weighted 3.0-T MR imaging-initial experience. Radiology 2009;250(3):784-792.
53. Ascher SM, Reinhold C. Imaging of cancer of the endometrium. Radiol Clin North Am 2002;40(3): 563-576.
54. Creasman WT. New gynecologic cancer staging. Gynecol Oncol 1995;58(2):157-158.
55. Odicino F, Tisi G, Rampinelli F, Miscioscia R, Sartori E, Pecorelli S. New development of the FIGO staging system. Gynecol Oncol 2007;107(1 Suppl 1): S8-S9.
56. Piver MS, Chung WS. Prognostic significance of cervical lesion size and pelvic node metastases in cervical carcinoma. Obstet Gynecol 1975;46(5): 507-510.
57. Subak LL, Hricak H, Powell CB, Azizi L, Stern JL. Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging. Obstet Gynecol 1995;86(1):43-50.
58. Kaur H, Silverman PM, Iyer RB, Verschraegen CF, Eifel PJ, Charnsangavej C. Diagnosis, staging, and surveillance of cervical carcinoma. AJR Am J Roentgenol 2003;180(6):1621-1631.
59. Nicolet V, Carignan L, Bourdon F, Prosmanne O. MR imaging of cervical carcinoma: a practical staging approach. RadioGraphics 2000;20(6): 1539-1549.
60. Okamoto Y, Tanaka YO, Nishida M, Tsunoda H, Yoshikawa H, Itai Y. MR imaging of the uterine cervix: imaging-pathologic correlation. RadioGraphics 2003;23(2):425-445.
61. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): cervical cancer. Version 1.2012. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Published August 8, 2011. Accessed January 5, 2012.
62. Zand KR, Reinhold C, Abe H, Maheshwari S, Mohamed A, Upegui D. Magnetic resonance imaging of the cervix. Cancer Imaging 2007;7:69-76.
63. Scheidler J, Heuck AF. Imaging of cancer of the cervix. Radiol Clin North Am 2002;40(3):577-590.
64. Sahdev A, Sohaib SA, Wenaden AE, Shepherd JH, Reznek RH. The performance of magnetic resonance imaging in early cervical carcinoma: a long-term experience. Int J Gynecol Cancer 2007;17(3): 629-636.
65. Sheu M, Chang C, Wang J, Yen M. MR staging of clinical stage I and IIa cervical carcinoma: a reappraisal of efficacy and pitfalls. Eur J Radiol 2001;38 (3):225-231.
66. Sahdev A, Jones J, Shepherd JH, Reznek RH. MR imaging appearances of the female pelvis after trachelectomy. RadioGraphics 2005;25(1):41-52.
67. Rockall AG, Ghosh S, Alexander-Sefre F, et al. Can MRI rule out bladder and rectal invasion in cervical cancer to help select patients for limited EUA? Gynecol Oncol 2006;101(2):244-249.
68. Hricak H, Powell CB, Yu KK, et al. Invasive cervical carcinoma: role of MR imaging in pretreatment work-up-cost minimization and diagnostic efficacy analysis. Radiology 1996;198(2):403-409.
69. Hricak H, Gatsonis C, Coakley FV, et al. Early invasive cervical cancer: CT and MR imaging in preoperative evaluation-ACRIN/GOG comparative study of diagnostic performance and interobserver variability. Radiology 2007;245(2):491-498.
70. Van Vierzen PB, Massuger LF, Ruys SH, Barentsz JO. Fast dynamic contrast enhanced MR imaging of cervical carcinoma. Clin Radiol 1998;53(3): 183-192.
71. Aoki Y, Sasaki M, Watanabe M, et al. High-risk group in node-positive patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation. Gynecol Oncol 2000;77(2):305-309.
72. Cheng X, Cai S, Li Z, Tang M, Xue M, Zang R. The prognosis of women with stage IB1-IIB node-positive cervical carcinoma after radical surgery. World J Surg Oncol 2004;2:47.
73. Larciprete G, Casalino B, Segatore MF, Jarvis S, Catarinella V, Cirese E. Pelvic lymphadenectomy for cervical cancer: extraperitoneal versus laparoscopic approach. Eur J Obstet Gynecol Reprod Biol 2006;126(2):259-263.
74. Savino L, Borruto F, Comparetto C, Massi GB. Radical vaginal hysterectomy with extraperitoneal pelvic lymphadenectomy in cervical cancer. Eur J Gynaecol Oncol 2001;22(1):31-35.
75. Chen J, Zhang Y, Liang B, Yang Z. The utility of diffusion-weighted MR imaging in cervical cancer. Eur J Radiol 2010;74(3):e101-e106.
76. Harry VN, Semple SI, Gilbert FJ, Parkin DE. Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol Oncol 2008;111(2): 213-220.
77. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 2009;105(2):107-108.
78. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105(2):103-104.
79. Bipat S, Glas AS, van der Velden J, Zwinderman AH, Bossuyt PM, Stoker J. Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review. Gynecol Oncol 2003;91(1):59-66.
80. Kupets R, Covens A. Is the International Federation of Gynecology and Obstetrics staging system for cervical carcinoma able to predict survival in patients with cervical carcinoma?: an assessment of clinimetric properties. Cancer 2001;92(4):796-804.
81. Choi HJ, Kim SH, Seo SS, et al. MRI for pretreatment lymph node staging in uterine cervical cancer. AJR Am J Roentgenol 2006;187(5):W538-W543.
82. Kim SH, Choi BI, Han JK, et al. Preoperative staging of uterine cervical carcinoma: comparison of CT and MRI in 99 patients. J Comput Assist Tomogr 1993;17(4):633-640.
83. Kim SH, Kim SC, Choi BI, Han MC. Uterine cervical carcinoma: evaluation of pelvic lymph node metastasis with MR imaging. Radiology 1994;190 (3):807-811.
84. Hricak H, Yu KK. Radiology in invasive cervical cancer. AJR Am J Roentgenol 1996;167(5):1101-1108.
85. Yang WT, Lam WW, Yu MY, Cheung TH, Metreweli C. Comparison of dynamic helical CT and dynamic MR imaging in the evaluation of pelvic lymph nodes in cervical carcinoma. AJR Am J Roentgenol 2000; 175(3):759-766.
86. Rockall AG, Sohaib SA, Harisinghani MG, et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 2005;23(12): 2813-2821.
87. Roy C, Le Bras Y, Mangold L, et al. Small pelvic lymph node metastases: evaluation with MR imaging. Clin Radiol 1997;52(6):437-440.
88. Whittaker CS, Coady A, Culver L, Rustin G, Padwick M, Padhani AR. Diffusion-weighted MR imaging of female pelvic tumors: a pictorial review. RadioGraphics 2009;29(3):759-774; discussion 774-778.
89. Lin G, Ho KC, Wang JJ, et al. Detection of lymph node metastasis in cervical and uterine cancers by diffusion-weighted magnetic resonance imaging at 3T. J Magn Reson Imaging 2008;28(1):128-135.
90. Kim JK, Kim KA, Park BW, Kim N, Cho KS. Feasibility of diffusion-weighted imaging in the differentiation of metastatic from nonmetastatic lymph nodes: early experience. J Magn Reson Imaging 2008;28(3):714-719.
91. Nakai G, Matsuki M, Inada Y, et al. Detection and evaluation of pelvic lymph nodes in patients with gynecologic malignancies using body diffusion-weighted magnetic resonance imaging. J Comput Assist Tomogr 2008;32(5):764-768.
92. Thoeny HC, Triantafyllou M, Birkhaeuser FD, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 2009;55(4): 761-769.